What is the evidence for repetitive magnetic stimulation (rMS) in treating chronic subjective tinnitus in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Evidence for Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Tinnitus

Repetitive transcranial magnetic stimulation (rTMS) shows modest short-term benefit for chronic subjective tinnitus but lacks robust long-term efficacy, and current evidence does not support its routine clinical use outside of research settings.

Guideline Position

The 2014 AAO-HNS Clinical Practice Guideline on tinnitus notably does not include rTMS among its recommended interventions 1. The guideline explicitly recommends cognitive-behavioral therapy (CBT), sound therapy, and hearing aids for patients with persistent bothersome tinnitus, while recommending against routine use of medications, dietary supplements, and acupuncture 1. The absence of rTMS from these recommendations reflects the insufficient evidence base at the time of guideline development.

Current Research Evidence

Meta-Analytic Findings

The most recent 2026 systematic review and meta-analysis provides the highest quality synthesis 2:

  • Overall effect: Pooled analysis of rTMS trials showed nonsignificant effects (SMD -0.15; 95% CI -0.37 to 0.07; I² = 0%) 2
  • Safety profile: Adverse events were mild and transient across noninvasive modalities 2
  • Comparison to alternatives: Bimodal stimulation demonstrated superior and more durable clinical improvements compared to rTMS 2

Short-Term vs Long-Term Efficacy

Multiple meta-analyses from 2020-2025 reveal a consistent pattern 3, 4, 5:

  • 1-week post-treatment: Significant improvement in Tinnitus Handicap Inventory (THI) scores (MD: -7.92) 4
  • 1-month post-treatment: Sustained benefit (MD: -8.52 to -14.86) 3, 4, 5
  • 6-month follow-up: Diminished effects (MD: -6.53), with some analyses showing no significant long-term benefit 3, 4
  • Immediate effects: No significant impact on Tinnitus Questionnaire (TQ) scores 3, 5

Individual Trial Data

The 2015 JAMA Otolaryngology RCT provides the most rigorous single-study evidence 6:

  • Response rate: 56% in active rTMS group vs 22% in placebo group (P < .005)
  • Protocol: 1-Hz rTMS, 2000 pulses/session, daily for 10 consecutive workdays
  • Durability: Improvements sustained through 26-week follow-up in responders
  • Limitations: Only 56% response rate means nearly half of patients derive no benefit

Clinical Interpretation

Why rTMS Shows Limited Efficacy

The mechanism of rTMS targets auditory cortex hyperactivity, but tinnitus involves distributed neural networks including limbic, attentional, and default mode systems 7. Single-site temporal cortex stimulation may be insufficient to modulate this complex pathophysiology.

Common Pitfalls to Avoid

  1. Overpromising results: The 56% response rate means 44% of patients will not benefit despite time and cost investment
  2. Ignoring superior alternatives: Bimodal stimulation shows more consistent and durable improvements 2
  3. Neglecting evidence-based first-line treatments: CBT, sound therapy, and hearing aids have stronger guideline support 1

Practical Clinical Algorithm

For adults with chronic subjective tinnitus:

  1. First-line interventions (strong guideline support):

    • Cognitive-behavioral therapy for all patients with bothersome tinnitus 1
    • Hearing aids if any degree of hearing loss present 1
    • Sound therapy as adjunctive treatment 1

  2. Consider rTMS only if:

    • Patient has failed first-line evidence-based treatments
    • Patient understands 44% likelihood of non-response
    • Access to research protocol or specialized center
    • Patient can commit to 10 consecutive daily sessions
    • Realistic expectations set for modest, potentially temporary benefit

  3. Prioritize bimodal stimulation over rTMS if available, given superior durability and consistency of response 2

  4. Do not offer rTMS as routine clinical care outside research settings given lack of guideline endorsement and modest effect sizes

Key Caveats

  • Most studies exclude patients with secondary tinnitus (Menière's disease, vestibular schwannoma, etc.), limiting generalizability 1
  • Optimal stimulation parameters (frequency, intensity, duration, target site) remain undefined 2
  • Cost-effectiveness has not been established
  • The 2023 ACR Appropriateness Criteria for tinnitus imaging does not address rTMS, focusing instead on diagnostic evaluation 8

Bottom line: While rTMS demonstrates statistical superiority over sham in some short-term outcomes, the clinical benefit is modest, inconsistent, and not durable enough to warrant routine use when evidence-based alternatives with stronger guideline support exist 1, 2.

References

1
Guideline

clinical practice guideline: tinnitus executive summary.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014

8
Guideline

acr appropriateness criteria® tinnitus: 2023 update.

Journal of the American College of Radiology, 2023

Related Questions

How does a cat function as adjunctive therapy for chronic subjective tinnitus?
What is the appropriate antimicrobial therapy for an 87-year-old patient with a urinary tract infection caused by cultured Escherichia coli, considering recent piperacillin‑tazobactam exposure and renal function?
How can secondary syphilis be suspected based on its dermatologic manifestations?
What are the appropriate treatment regimens and alternatives for a penicillin‑allergic patient with secondary syphilis, including options for pregnant or HIV‑positive individuals?
After completing oral vancomycin for Clostridioides difficile colonization, should I prescribe nitrofurantoin (Macrobid) for this patient?
In secondary syphilis, what supportive or symptomatic treatments can be given in addition to antibiotic therapy?
Is aspirin 80 mg tablet as effective as aspirin 100 mg tablet for low‑dose antiplatelet therapy in adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.